Docmode Health Technologies Ltd (DHTL) — shareholding pattern, promoter holding, financials and share price
About Docmode Health Technologies Ltd (DHTL)
Docmode Health Technologies Ltd operates in the Healthcare Research, Analytics & Technology industry, within the Healthcare sector. It trades on the NSE as DHTL and on the BSE under scrip code 79225. Its ISIN is INE0OGG01015.
Incorporated in 2017, Docmode Health Technologies Ltd is in the business of offering integrated learning solutions through online and offline learning models for healthcare professionals [1]
Docmode Health Technologies Limited specializes in healthcare technology, focusing on transforming medical education, research, and practice through innovative digital platforms.
The company's products, such as iNutrimon and AIDE, have achieved significant adoption, reflecting its capability to deliver impactful tools to healthcare professionals.
Listed peers in Healthcare Research, Analytics & Technology: Bilcare Ltd, Jeevan Scientific Technology Ltd, Globalspace Technologies Ltd, Novelix Pharmaceuticals Ltd, Adeshwar Meditex Ltd, Vanta Bioscience Ltd.
Valuation & Returns
10 Jul 2026At ₹36.8 a share on 10 Jul 2026, Docmode Health Technologies Ltd (DHTL) was valued at a price-to-earnings ratio of -7.87x against an industry P/E of 61.73x and a price-to-book of 1.39x on a book value of ₹26.56 per share. Solomo computes return on equity of -17.77% and return on capital employed of 0.86% from filed results.
- P/E
- -7.87x
- Industry P/E
- 61.73x
- P/B
- 1.39x
- EPS (TTM)
- ₹-6.45
- Book value / share
- ₹26.56
- ROE
- -17.77%
- ROCE
- 0.86%
- ROA
- -3.87%
- Debt / equity
- 0.9x
- Dividend yield
- 0%
- EBITDA margin
- 1.02%
- 52-week range
- ₹35.05 – ₹125.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Docmode Health Technologies Ltd (DHTL) reported revenue of ₹41.71 crore, net profit of ₹-2.03 crore and earnings per share of ₹-6.46. That compares with revenue of ₹39.93 crore and net profit of ₹0.19 crore in Mar 2024. Figures are consolidated, as filed with the exchanges.
In the quarter ended Sep 2025, revenue was ₹17.85 crore and net profit ₹-0.09 crore (consolidated).
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 7.1 | 12.42 | 32.88 | 39.93 | 41.71 |
| Net profit (₹ cr) | 0.55 | 0.92 | 1.95 | 0.19 | -2.03 |
| EPS (₹) | - | - | 8.5 | 0.6 | -6.46 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 43.20% | 49.82% | 4.40% |
| Stock price CAGR | - | - | -20% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 29.5% of Docmode Health Technologies Ltd (DHTL). Market capitalisation was ₹12 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2024.
Largest disclosed public shareholders in Mar 2026: BINDI KUNAL MEHTA 16.58%, ANIL KHANNA 12.77%, AALOK BANSIDHAR PATHAK 12.73%, RAMESH KUMAR JAIN 5.09%, RAMESH JAIN 3.82%, NIKHIL R JAIN 2.55%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 29.5% | - | - | - | - |
| Sep 2025 | 30.86% | - | - | - | - |
| Mar 2025 | 47.44% | - | - | - | - |
| Dec 2024 | 47.44% | - | - | - | - |
| Sep 2024 | 47.44% | - | - | - | - |
| Mar 2024 | 47.44% | - | - | - | - |